Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open‐label phase I dosage …

GG Illei, Y Shirota, CH Yarboro… - … : Official Journal of …, 2010 - Wiley Online Library
Objective To assess the safety of interleukin‐6 receptor inhibition and to collect preliminary
data on the clinical and immunologic efficacy of tocilizumab in patients with systemic lupus …
被引用次数：652 相关文章

[引用][C] Tocilizumab in Systemic Lupus Erythematosus: Data on Safety, Preliminary Efficacy, and Impact on Circulating Plasma Cells From an Open-Label Phase I …

GG ILLEI, Y SHIROTA, CH YARBORO… - Arthritis and …, 2010 - pascal-francis.inist.fr
Tocilizumab in Systemic Lupus Erythematosus: Data on Safety, Preliminary Efficacy, and
Impact on Circulating Plasma Cells From an Open-Label Phase I Dosage-Escalation Study …

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage …

GG Illei, Y Shirota, CH Yarboro… - Arthritis and …, 2010 - pubmed.ncbi.nlm.nih.gov
Objective To assess the safety of interleukin-6 receptor inhibition and to collect preliminary
data on the clinical and immunologic efficacy of tocilizumab in patients with systemic lupus …

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage …

GG Illei, Y Shirota, CH Yarboro, J Daruwalla… - Arthritis and …, 2010 - europepmc.org
Objective To assess the safety of interleukin-6 receptor inhibition and to collect preliminary
data on the clinical and immunologic efficacy of tocilizumab in patients with systemic lupus …

Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open‐label phase I dosage …

GG Illei, Y Shirota, CH Yarboro… - … : Official Journal of …, 2010 - Wiley Online Library
Objective To assess the safety of interleukin‐6 receptor inhibition and to collect preliminary
data on the clinical and immunologic efficacy of tocilizumab in patients with systemic lupus …

[引用][C] Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage …

I GG - Arthritis Rheum, 2010 - cir.nii.ac.jp
Tocilizumab in systemic lupus erythematosus : data on safety, preliminary efficacy, and impact
on circulating plasma cells from an open-label phase I dosage-escalation study | CiNii …
[HTML] nih.gov

[HTML][HTML] Tocilizumab in Systemic Lupus Erythematosus–Safety, Preliminary Efficacy, and Impact on Circulating Plasma Cells

GG Illei, Y Shirota, CH Yarboro, J Daruwalla… - Arthritis and …, 2010 - ncbi.nlm.nih.gov
Objective To assess the safety of interleukin-6 receptor inhibition and to collect preliminary
data on clinical and immunologic efficacy of tocilizumab in patients with systemic lupus …

Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open‐label phase I dosage …

GG Illei, Y Shirota, CH Yarboro, J Daruwalla… - Arthritis & …, 2010 - infona.pl
Objective To assess the safety of interleukin‐6 receptor inhibition and to collect preliminary
data on the clinical and immunologic efficacy of tocilizumab in patients with systemic lupus …

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage …

GG Illei, Y Shirota, CH Yarboro, J Daruwalla… - Arthritis and …, 2010 - europepmc.org
Objective To assess the safety of interleukin-6 receptor inhibition and to collect preliminary
data on the clinical and immunologic efficacy of tocilizumab in patients with systemic lupus …

[引用][C] Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage …

GG Illei, Y Shirota, CH Yarboro, J Daruwalla… - Arthritis & …, 2010 - cir.nii.ac.jp
Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact
on circulating plasma cells from an open-label phase I dosage-escalation study | CiNii …